Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/34746
Tipo
ArtículoDerechos de autor
Acceso abierto
Objetivos de Desarrollo Sostenible
3 Saúde e Bem-EstarColecciones
Metadatos
Mostrar el registro completo del ítem
PERSISTENT INFLAMMATION DURING ANTI-TUBERCULOSIS TREATMENT WITH DIABETES COMORBIDITY
Diabetes mellitus
Humano
Imunologia
Doença infecciosa
Inflamação
Microbiologia
Tuberculose
Diabetes mellitus
Human
Immunology
Infectious disease
Inflammation
Microbiology
Tuberculosis
Autor
Afiliación
National Institutes of Health. National Institute for Research in Tuberculosis. International Center for Excellence in Research. Chennai, India.
Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brazil / Faculdade de Tecnologia e Ciências. Salvador, BA, Brazil.
Prof. M. Viswanathan Diabetes Research Center. Chennai, India.
Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil / Universidade Salvador. Laureate Universities. Salvador, BA, Brasil.
Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil / Faculdade de Tecnologia e Ciências. Salvador, BA, Brazil.
Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil.
University of Massachusetts Medical School. Worcester, United States.
National Institute for Research in Tuberculosis. Chennai, India.
Prof. M. Viswanathan Diabetes Research Center. Chennai, India.
National Institutes of Health. National Institute for Research in Tuberculosis. International Center for Excellence in Research. Chennai, India.
Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brazil / Faculdade de Tecnologia e Ciências. Salvador, BA, Brazil / Universidade Salvador. Laureate Universities. Salvador, BA, Brasil.
University of Massachusetts Medical School. Worcester, United States.
Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brazil / Faculdade de Tecnologia e Ciências. Salvador, BA, Brazil.
Prof. M. Viswanathan Diabetes Research Center. Chennai, India.
Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil / Universidade Salvador. Laureate Universities. Salvador, BA, Brasil.
Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil / Faculdade de Tecnologia e Ciências. Salvador, BA, Brazil.
Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil.
University of Massachusetts Medical School. Worcester, United States.
National Institute for Research in Tuberculosis. Chennai, India.
Prof. M. Viswanathan Diabetes Research Center. Chennai, India.
National Institutes of Health. National Institute for Research in Tuberculosis. International Center for Excellence in Research. Chennai, India.
Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brazil / Faculdade de Tecnologia e Ciências. Salvador, BA, Brazil / Universidade Salvador. Laureate Universities. Salvador, BA, Brasil.
University of Massachusetts Medical School. Worcester, United States.
Resumen en ingles
Diabetes mellitus (DM) increases risk for pulmonary tuberculosis (TB) and adverse treatment outcomes. Systemic hyper-inflammation is characteristic in people with TB and concurrent DM (TBDM) at baseline, but the impact of TB treatment on this pattern has not been determined. We measured 17 plasma cytokines and growth factors in longitudinal cohorts of Indian and Brazilian pulmonary TB patients with or without DM. Principal component analysis revealed virtually complete separation of TBDM from TB individuals in both cohorts at baseline, with hyper-inflammation in TBDM that continued through treatment completion at six months. By one year after treatment completion, there was substantial convergence of mediator levels between groups within the India cohort. Non-resolving systemic inflammation in TBDM comorbidity could reflect delayed lesion sterilization or non-resolving sterile inflammation. Either mechanism portends unfavorable long-term outcomes including risk for recurrent TB and for damaging immune pathology.
Palabras clave en portugues
CitocinasDiabetes mellitus
Humano
Imunologia
Doença infecciosa
Inflamação
Microbiologia
Tuberculose
Palabras clave en ingles
CytokinesDiabetes mellitus
Human
Immunology
Infectious disease
Inflammation
Microbiology
Tuberculosis
Compartir